Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1826 in combination with other therapies in advanced solid tumors
NCT06703177Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1826 in solid tumor, sponsored by Suzhou Suncadia Biopharmaceutical. Started Feb 2025; status: recruiting.
02
Drugs
SHR-1826
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06703177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703177.